Hunan Warrant Pharmaceutical (SHA:688799) is planning to invest up to 500 million yuan in the phase two expansion of its high-end active pharmaceutical ingredient (API) and intermediate green manufacturing base in Changsha in China's Hunan Province.
The expansion is expected to scale up API production, strengthen the company's green manufacturing edge and drive long-term growth, according to a Monday filing with the Shanghai bourse.
Annual output will be 3,000 tons of high-end APIs and intermediates.
Construction is expected to take between one and three years.
Shares of the company were down 1% Monday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。